FDA approves IND Application for Ph 2/3 Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “As a high-potential candidate in Junshi Biosciences’ next-generation immuno-oncology portfolio (I-O 2.0), JS207 has undergone a series of proof-of-concept (POC) studies targeting prevalent cancers in China and globally. In this ongoing Phase 2/3 clinical trial evaluating neoadjuvant therapy for resectable lung cancer, we have chosen to directly challenge first-generation PD-1 monoclonal antibodies with JS207. By harnessing cutting-edge innovative therapies, we aim to offer more patients better treatments and a better future. The international regulatory authorities have recognized our clinical demand-driven R&D plus scientifically rigorous study design, and their validation is highly encouraging. Moving forward, we will accelerate our global development efforts to make JS207 a cornerstone of the I-O 2.0 porfolio and achieve evolutionary breakthroughs in immuno-oncology.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo